Reagent composition for detection of non-hematopoietic tumor and use thereof
US12146881B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jun 14, 2023 |
| Grant date | Nov 19, 2024 |
| Priority date | — |
| Expiry date | Jun 14, 2043 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/70596
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention provides a reagent composition for detection of a non-hematopoietic tumor and use thereof. Said reagent composition includes three sets of antibodies, with the first set of antibodies including an anti-CD9 antibody, an anti-GD2 antibody, an anti-CD3 antibody, an anti-CD4 antibody, an anti-CD56 antibody, an anti-CD36 antibody, an anti-CD81, and an anti-CD45 antibody; the second set of antibodies including an anti-HLA-ABC antibody, an anti-CD38 antibody, an anti-CD19 antibody, an anti-CD56 antibody, an anti-CD36 antibody, an anti-CD7 antibody, and an anti-CD45 antibody; the third set of antibodies including anti-cytoplasmic cytokeratin antibodies; wherein the first set of antibodies and the second set of antibodies are respectively used for samples in separate tubes, and the third set of antibodies is used for the sample in the same tube as the second set of antibodies. The reagent composition of the present invention can be applied for flow cytometry screening, diagnosis and/or follow-up detection of a non-hematopoietic tumor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.